Premium
Ablation of interferon regulatory factor 4 in T cells induces “memory” of transplant tolerance that is irreversible by immune checkpoint blockade
Author(s) -
Zhang Hedong,
Wu Jie,
Zou Dawei,
Xiao Xiang,
Yan Hui,
Li Xian C.,
Chen Wenhao
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15196
Subject(s) - immune checkpoint , blockade , cancer research , medicine , irf4 , t cell , immunology , interferon regulatory factors , immune system , transplantation , transplant rejection , immune tolerance , transcription factor , immunotherapy , biology , microbiology and biotechnology , receptor , innate immune system , biochemistry , gene
Achieving transplant tolerance remains the ultimate goal in the field of organ transplantation. We demonstrated previously that ablation of the transcription factor interferon regulatory factor 4 ( IRF 4) in T cells induced heart transplant acceptance by driving allogeneic CD 4 + T cell dysfunction. Herein, we showed that heart‐transplanted mice with T cell‐specific IRF 4 deletion were tolerant to donor‐specific antigens and accepted the subsequently transplanted donor‐type but not third‐party skin allografts. Moreover, despite the rejection of the primary heart grafts in T cell‐specific Irf4 knockout mice under immune checkpoint blockade, the establishment of donor‐specific tolerance in these mice was unhindered. By tracking alloantigen‐specific CD 4 + T cells in vivo, we revealed that checkpoint blockade restored the expression levels of the majority of wild‐type T cell‐expressed genes in Irf4 ‐deficient T cells on day 6 post‐heart grafting, indicating the initial reinvigoration of Irf4 ‐deficient T cells. Nevertheless, checkpoint blockade did not restore cell frequency, effector memory cell generation, and IFN ‐γ/ TNF ‐α production of Irf4 −/− alloreactive T cells at day 30 post‐heart grafting. Hence, targeting IRF 4 represents a potential therapeutic strategy for driving intrinsic T cell dysfunction and achieving alloantigen‐specific transplant tolerance.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom